BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 30, 2006
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 3Q06 EPS est 3Q06 EPS actual Outcome Growth from 3Q05 10/27 cls Wk chg % chg Mcap chg 10/27 Mcap
Affymetrix (AFFX) -$0.08 -$0.06 Beat by $0.02 NA $26.22 $3.49 15% $234.7 $1,763.2
3Q06 EPS excludes a $0.15 per share restructuring charge. The microarray company's 3Q06 revenues were up 2% to $84.7M from $83.4M in the same period last year.
Amgen (AMGN) $0.98 $1.04 Beat by $0.06 22% $75.52 $1.57 2% $1,854.2 $89,189.1
Sales were up 15% to $3.5B from $3.1B in 3Q05. Sales of anemia drug Aranesp were up 27% to $1.1B vs. 3Q05, and sales of neutropenia products Neupogen and Neulasta were up 13% to $998M. For the year, AMGN raised its adjusted EPS guidance to $3.85-$3.95 from $3.75-$3.85, and narrowed its revenue guidance to $14.1-$14.3B from $14-$14.3B.
Applied Bio (ABI) (A) $0.25 $0.29 Beat by $0.04 26% $37.63 $4.16 12% $757.4 $6,851.6
The instrument company posted revenues of $476.3M, up 15% from $415.5M in the prior year's quarter.
AstraZeneca (LSE:AZN; AZN) $0.97 $1.01 Beat by $0.04 33% $59.16 -$7.11 -11% -$11,105.8 $92,407.9
Sales increased 13% to $6.5B from $5.8B in 3Q05. AZN raised its FY06 EPS guidance to $3.85-$3.95 from $3.60-$3.90.
BioSite (BSTE) $0.54 $0.49 Missed by $0.05 -28% $47.27 -$1.66 -3% -$30.3 $864.2
BSTE...

Read the full 1380 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >